source
- UniQure submits experimental Huntington's gene therapy to FDA for accelerated reviewUniQure announced that it has filed its experimental gene therapy for Huntington's disease with the U.S. Food and Drug Administration, seeking accelerated approval. The submission follows earlier…
- Teva's anti-IL-15 antibody meets primary endpoint in phase 2a celiac disease trialTeva Pharmaceuticals reported that its anti‑interleukin‑15 antibody, TEV‑408, achieved the primary endpoint in a phase 2a study of 50 adults with celiac disease. Participants received a single dose…